Advertisement

Pituitary

, Volume 10, Issue 2, pp 129–133 | Cite as

Normal levels of serum IGF-I: determinants and validity of current reference ranges

  • G. BrabantEmail author
  • H. Wallaschofski
Article

Abstract

Insulin like growth factor I (IGF-I) represents the key marker for the evaluation of Growth hormone (GH) status. As a large number of determinants including age, gender, genetic factors, nutrition, and disease states influence IGF-I serum levels, accurate normative data are essential to translate patient data into diagnostic meaning or even use IGF-I levels for adequate monitoring of patients with an over- or under-active GH axis. Even though reference ranges have been developed in large cohorts of healthy subjects, the dependency of these data on a given assay technology argues for assay specific normative data for IGF-I.

Keywords

IGF-I Gender Age Genetics Nutrition Disease dependency 

References

  1. 1.
    Giustina A, Veldhuis JD (1998) Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 19(6):717–797PubMedCrossRefGoogle Scholar
  2. 2.
    Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society (2000) GH Research Society. J Clin Endocrinol Metab 85(11):3990–3993CrossRefGoogle Scholar
  3. 3.
    Shalet SM, Toogood A, Rahim A, Brennan BM (1998) The diagnosis of growth hormone deficiency in children and adults. Endocr Rev 19(2):203–223PubMedCrossRefGoogle Scholar
  4. 4.
    Brabant G (2003) Insulin-like growth factor-I: marker for diagnosis of acromegaly and monitoring the efficacy of treatment. Eur J Endocrinol 148(Suppl 2):S15–S20PubMedCrossRefGoogle Scholar
  5. 5.
    Cohen P (2006) Overview of the IGF-I system. Horm Res 65(Suppl 1):3–8PubMedCrossRefGoogle Scholar
  6. 6.
    Hwa V, Oh Y, Rosenfeld RG (1999) The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev 20(6):761–787PubMedCrossRefGoogle Scholar
  7. 7.
    Yakar S, Sun H, Zhao H, Pennisi P, Toyoshima Y, Setser J, Stannard B, Scavo L, Leroith D (2005) Metabolic effects of IGF-I deficiency: lessons from mouse models. Pediatr Endocrinol Rev 3(1):11–19PubMedGoogle Scholar
  8. 8.
    Brabant G, von zur Muhlen A, Wuster C, Ranke MB, Kratzsch J, Kiess W, et al (2003) Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study. Horm Res 60(2):53–60PubMedCrossRefGoogle Scholar
  9. 9.
    Milani D, Carmichael JD, Welkowitz J, Ferris S, Reitz RE, Danoff A, Kleinberg DL (2004) Variability and reliability of single serum IGF-I measurements: impact on determining predictability of risk ratios in disease development. J Clin Endocrinol Metab 89(5):2271–2274PubMedCrossRefGoogle Scholar
  10. 10.
    Borofsky ND, Vogelman JH, Krajcik RA, Orentreich N (2002) Utility of insulin-like growth factor-1 as a biomarker in epidemiologic studies. Clin Chem 48(12):2248–2251PubMedGoogle Scholar
  11. 11.
    Smith PJ, Spurrell EL, Coakley J, Hinds CJ, Ross RJM, Krainer AR, Chew SL (2002) An exonic splicing enhancer in human IGF-I pre-mRNA mediates recognition of alternative exon 5 by the serine-arginine protein splicing factor-2/alternative splicing factor. Endocrinology 143:146–154PubMedCrossRefGoogle Scholar
  12. 12.
    Hong Y, Brismar K, Hall K, Pedersen NL, de Faire U (1997) Associations between insulin-like growth factor-I (IGF-I), IGF-binding protein-1, insulin and other metabolic measures after controlling for genetic influences: results from middle-aged and elderly monozygotic twins. J Endocrinol 153(2):251–257PubMedCrossRefGoogle Scholar
  13. 13.
    Vaessen N, Heutink P, Janssen JA, Witteman JC, Testers L, Hofman A, Lamberts SW, Oostra BA, Pols HA, van Duijn CM (2001) A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes 50(3):637–642PubMedCrossRefGoogle Scholar
  14. 14.
    Lofqvist C, Andersson E, Gelander L, Rosberg S, Blum WF, Albertsson Wikland K (2001) Reference values for IGF-I throughout childhood and adolescence: a model that accounts simultaneously for the effect of gender, age, and puberty. J Clin Endocrinol Metab 86:5870–5876PubMedCrossRefGoogle Scholar
  15. 15.
    Bereket A, Turan S, Omar A, Berber M, Ozen A, Akbenlioglu C, Haklar G (2006) Serum IGF-I and IGFBP-3 levels of Turkish children during childhood and adolescence: establishment of reference ranges with emphasis on puberty. Horm Res 65:96–105PubMedCrossRefGoogle Scholar
  16. 16.
    Juul A, Bang P, Hertel NT, Main K, Dalgaard P, Jorgensen K, Muller J, Hall K, Skakkebaek NE (1994) Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 78:744–752PubMedCrossRefGoogle Scholar
  17. 17.
    Ranke MB, Osterziel KJ, Schweizer R, Schuett B, Weber K, Robbel P, Vornwald A, Blumenstock G, Elmlinger MW (2003) Reference levels of insulin-like growth factor I in the serum of healthy adults: comparison of four immunoassays. Clin Chem Lab Med 41:1329–1334PubMedCrossRefGoogle Scholar
  18. 18.
    Elmlinger MW, Kuhnel W, Weber MM, Ranke MB (2004) Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3). Clin Chem Lab Med 42:654–664PubMedCrossRefGoogle Scholar
  19. 19.
    Ho KK, Gibney J, Johannsson G, Wolthers T (2006) Regulating of growth hormone sensitivity by sex steroids: implications for therapy. Front Horm Res 35:115–128PubMedGoogle Scholar
  20. 20.
    Caufriez A, Frankenne F, Hennen G, Copinschi G (1993) Regulation of maternal IGF-I by placental GH in normal and abnormal human pregnancies. Am J Physiol 265(4 Pt 1):E572–E577PubMedGoogle Scholar
  21. 21.
    Monaghan JM, Godber IM, Lawson N, Kaur M, Wark G, Teale D, Hosking DJ (2004) Longitudinal changes of insulin-like growth factors and their binding proteins throughout normal pregnancy. Ann Clin Biochem 41:220–226PubMedCrossRefGoogle Scholar
  22. 22.
    Thissen JP, Ketelsleger JM (1994) Underwood LE Nutritional regulation of the insulin-like growth factors. Endocr Rev 15:80–101PubMedCrossRefGoogle Scholar
  23. 23.
    Lieberman SA, Butterfield GE, Harrison D, Hoffman AR (1994) Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 78:404–410PubMedCrossRefGoogle Scholar
  24. 24.
    Gianotti L, Broglio F, Ramunni J, Lanfranco F, Gauna C, Benso A, Zanello M, Arvat E, Ghigo E (1998) The activity of GH/IGF-I axis in anorexia nervosa and in obesity: a comparison with normal subjects and patients with hypopituitarism or critical illness. Eat Weight Disord 3:64–70PubMedGoogle Scholar
  25. 25.
    Ponzer S, Tidermark J, Brismar K, SoderqvistA&Cederholm T (1999) Nutritional status, insulin-like growth factor-I and quality of life in elderly women with hip fractures. Clin Nutr 18:241–246PubMedCrossRefGoogle Scholar
  26. 26.
    Veldhuis JD, Iranmanesh A (1996) Physiological regulation of the human growth hormone (GH)-insulin-like growth factor type I (IGF-I) axis: predominant impact of age, obesity, gonadal function, and sleep. Sleep 19(Suppl 10):S221–S224PubMedGoogle Scholar
  27. 27.
    Schneider HJ, Saller B, Klotsche J, Marz W, Erwa W, Wittchen HU, Stalla GK (2006) Opposite associations of age-dependent insulin-like growth factor-I standard deviation scores with nutritional state in normal weight and obese subjects. Eur J Endocrinol 154(5):699–706PubMedCrossRefGoogle Scholar
  28. 28.
    de Boer H, Blok GJ, Voerman B, Derriks P, van der Veen E (1996) Changes in subcutaneous and visceral fat mass during growth hormone replacement therapy in adult men. Int J Obes Relat Metab Disord 20(6):580–587PubMedGoogle Scholar
  29. 29.
    Chen JW, Nielsen MF, Caumo A, Vilstrup H, Christiansen JS, Frystyk J (2006) Changes in bioactive IGF-I and IGF-binding protein-1 during an oral glucose tolerance test in patients with liver cirrhosis. Eur J Endocrinol 155:285–292PubMedCrossRefGoogle Scholar
  30. 30.
    Barkan AL, Beitins IZ, Kelch RP (1988) Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. J Clin Endocrinol Metab 67:69–73PubMedCrossRefGoogle Scholar
  31. 31.
    Rabkin R, Schaefer F ( 2004) New concepts: growth hormone, insulin-like growth factor-I and the kidney. Growth Horm IGF Res 14:270–276PubMedCrossRefGoogle Scholar
  32. 32.
    Blum WF, Ranke MB, Kietzmann K, Tonshoff B, Mehls O (1991) Growth hormone resistance and inhibition of somatomedin activity by excess of insulin-like growth factor binding protein in uraemia. Pediatr Nephrol 5:539–544PubMedCrossRefGoogle Scholar
  33. 33.
    Heald AH, Anderson SG, Ivison F, Laing I, Gibson JM, Cruickshank K (2003) C-reactive protein and the insulin-like growth factor (IGF)-system in relation to risk of cardiovascular disease in different ethnic groups. Atherosclerosis 170:79–86PubMedCrossRefGoogle Scholar
  34. 34.
    Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T (2002) Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 106(8):939–944PubMedCrossRefGoogle Scholar
  35. 35.
    Laughlin GA, Barrett-Connor E, Criqui MH, Kritz-Silverstein D (2004) The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J Clin Endocrinol Metab 89(1):114–120PubMedCrossRefGoogle Scholar
  36. 36.
    Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363:1346–1353PubMedCrossRefGoogle Scholar
  37. 37.
    Samani AA, Yakar S, LeRoith D, Brodt P (2007) The Role of the IGF System in Cancer Growth and Metastasis: Overview and recent insights. Endocr Rev 28:20–47PubMedCrossRefGoogle Scholar
  38. 38.
    Jenkins PJ, Mukherjee A, Shalet SM (2006) Does growth hormone cause cancer? Clin Endocrinol (Oxf) 64:115–121CrossRefGoogle Scholar
  39. 39.
    von Wichert G, Jehle PM, Hoeflich A, Koschnick S, Dralle H, Wolf E, Wiedenmann B, Boehm BO, Adler G, Seufferlein T (2000) Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res 60:4573–4581Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.Department of EndocrinologyChristie HospitalManchesterUK
  2. 2.Department of Gastroenterology, Endocrinology and NutritionUniversity of GreifswaldGreifswaldGermany

Personalised recommendations